uniQure N.V. Q3 2025 Earnings Recap

QURE Q3 2025 November 10, 2025

Get alerts when QURE reports next quarter

uniQure N.V. delivered strong top-line results from its pivotal Phase 1/2 study of AMT-130, marking a significant milestone in Huntington's disease treatment, although FDA feedback introduces uncertainty regarding the expected BLA submission timeline.

Earnings Per Share Miss

$-1.38 vs $-0.85 est.

-62.4% surprise

Revenue Miss

3701000 vs 4844330 est.

-23.6% surprise

Market Reaction

1-Day -5.9%

5-Day +7.52%

30-Day -18.17%

See QURE alongside your other holdings

Add to your portfolio — free

Key Takeaways

AMT-130 demonstrated a statistically significant 75% slowing of disease progression over three years, meeting pivotal study endpoints.
The FDA's recent feedback has raised concerns over the adequacy of AMT-130's evidence for a BLA submission, leading to uncertainty regarding the submission timeline.
In addition to Huntington's, uniQure is advancing AMT-260 for epilepsy, with active recruitment of clinical sites and initial positive data expected next year.
Results from the Phase 1/2a trial of AMT-191 for Fabry disease show promising enzyme activity, with one patient successfully withdrawing from enzyme replacement therapy.
uniQure remains committed to engaging with the FDA to expedite the path forward for AMT-130 despite the recent setbacks.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit QURE on AllInvestView.

Previous Q2 2025